Cargando…

Progress and opportunities in measuring the burden of Chronic Kidney Disease

Detalles Bibliográficos
Autores principales:	Vart, Priya, Heerspink, Hiddo J.L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241022/ https://www.ncbi.nlm.nih.gov/pubmed/35781927 http://dx.doi.org/10.1016/j.lanepe.2022.100447

Ejemplares similares

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial
por: Vart, Priya, et al.
Publicado: (2023)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Informing clinical decision making during a pandemic — a call for better preparedness
por: Vart, Priya, et al.
Publicado: (2023)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
por: Koshino, Akihiko, et al.
Publicado: (2022)

COVID-19: An opportunity to combat the burden of poor mental health in Australian workplaces
por: Taouk, Yamna, et al.
Publicado: (2022)

Increase in the global burden of chronic kidney disease: might it be attributable to air pollution?
por: Copur, Sidar, et al.
Publicado: (2022)

Besieged on all sides: the future burden of high-temperature-related kidney disease
por: Chu, Lingzhi, et al.
Publicado: (2023)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Productivity-adjusted life-years: new measure of disease burden
Publicado: (2021)

Electronic patient-reported outcomes in chronic kidney disease
por: Anderson, Nicola, et al.
Publicado: (2022)

Detecting chronic kidney disease by electrocardiography
por: Kooman, Jeroen P.
Publicado: (2023)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
por: Schnell, Oliver, et al.
Publicado: (2023)

An integrated approach towards a public health perspective on chronic kidney disease
por: Dorgelo, Annemiek, et al.
Publicado: (2022)

The role of kidney registries in expediting large-scale collection of patient-reported outcome measures for people with chronic kidney disease
por: van der Veer, Sabine N, et al.
Publicado: (2021)

Brazilian public policy for chronic kidney disease prevention: challenges and perspectives
por: Silva, Patrícia Aparecida Barbosa, et al.
Publicado: (2020)

Comments on: “Comparison of Methods Study between a Photonic Crystal Biosensor and Certified ELISA to Measure Biomarkers of Iron Deficiency in Chronic Kidney Disease Patients”
por: Abbas, Naseem, et al.
Publicado: (2020)

Advancing equity, diversity, and inclusion in the American College of Neuropsychopharmacology (ACNP): advances, challenges, and opportunities to accelerate progress
por: Henningfield, Jack E., et al.
Publicado: (2020)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Reducing the gap of chronic kidney disease in low- and middle-income countries: what is missing?
por: López, Darío Sebastián, et al.
Publicado: (2023)

Empowering community control over alcohol availability as a suicide and self-harm prevention measure: Policy opportunity in Aotearoa New Zealand
por: Boden, J., et al.
Publicado: (2022)

Evidence of chronic kidney injury in patients not meeting KDIGO criteria for chronic kidney disease
por: Alvarez-Llamas, Gloria, et al.
Publicado: (2022)

Opportunities and challenges in understanding complex functional materials
por: Goodwin, Andrew L.
Publicado: (2019)

Clinicians should be more prone to examine children with chronic kidney disease in terms of vitamin D deficiency
por: Balta, Sevket, et al.
Publicado: (2013)

Opportunities and challenges for digital morphology
por: Ziegler, Alexander, et al.
Publicado: (2010)

Progress in chronic graft-versus-host disease
por: Martin, Paul J
Publicado: (2011)

India's economic growth and disease burden in relation to air pollution
por: Tyagi, Bhishma
Publicado: (2022)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality
por: Gonzalez-Martin, Guillermo, et al.
Publicado: (2020)

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial
por: Stern, Edward P., et al.
Publicado: (2022)

Thiazides in chronic kidney disease: “back to the future”
por: de la Espriella, Rafael, et al.
Publicado: (2022)

More on the invisibility of chronic kidney disease… and counting
por: Carriazo, Sol, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ofeldqu2b549bnnphq5f7h0ehb